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Bhamidipati et al Perioperative Managementquestion the necessity of this threshold. In fact, moderate
control in this study was independently associated with
lower mortality and major complications among patients
after isolated coronary revascularization. On the basis of
our findings, we believe that moderate glycemic control
(150 mg/dL  15%) may be superior to tight control
(126 mg/dL) and entails few hypoglycemic events. Fur-
ther randomized prospective studies evaluating the optimal
postoperative glycemic regimen are necessary.
We thank Kenneth W. Scully and Judy G. Smith for their assis-
tance with data collection and editorial perspective.P
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Dr Anthony P. Furnary (Portland, Ore). Dr Ailawadi, since I
have to make this short, I really can’t make it sweet. I thought your
title was very clever, but the simple statistical fact is that neither
the title nor the conclusions are supported in any way by the
data presented, nor is it possible that any difference between tightrdiovascular Surgery c Volume 141, Number 2 549
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Mand moderate control, if it did actually exist, could have ever been
statistically detected in this study.
Let me explain. There are 134 patients in the tight group and
2700 in the moderate group. Because of the lack of a sufficient
number of patients in the tight group, the study was markedly un-
derpowered to detect any differences between the tight and mod-
erate groups. Power analysis reveals that the estimated power of
this study to detect a 1% absolute reduction in mortality between
these 2 groups was only 3%, nowhere near the 80% power sought
to ensure a valid finding. A quick c2 analysis comparing your mor-
tality data between these 2 groups shows a P value of .6. Even if
there had been no deaths at all in the tight group, the P value would
have still been insignificant at .1.
Furthermore, your study is based entirely on retrospective data
abstracted from an administrative—read ‘‘billing’’—database. Not
a clinical database, not an STS database, an administrative data-
base. Clinical outcomes from these databases are ‘‘assumed’’ by
interpreting coding information that is applied to patient charts
by hospital coders after discharge. Then, rather than using estab-
lished STS predicted risk scores, which you had, for logistic risk
adjustment, a new regression model was created.
What you have shown is that moderate control is superior to
no control at all, and this is a finding that is supported by 15
years of published literature on the subject. Moderate control
reduced mortality by 40% relative to no control. Interestingly,
the point estimate for tight control shows a 50% reduction in
mortality relative to the no control group. Again, however,
there weren’t enough patients to bring that point estimate to
statistical significance; even had there been no deaths at all
in the tight control group, it wouldn’t have made it into the
equation. To take those results and imply that moderate control
is superior to tight control when they weren’t even directly
compared, simply because it didn’t make it into the equation
because of the low number of patients, is either wishful think-
ing or misleading marketing rhetoric that is not supported by
your statistical data.
I have similar concerns about your morbidity statistics and con-
clusions. I don’t have time to go into them here. In addition, how-
ever, of the 5 major complications that you have analyzed, 3 of
them—stroke, prolonged ventilation, and reoperation—have never
ever been shown to be associated with, let alone caused by, hyper-
glycemia in cardiac surgical patients. Thus the treatment studied,
glycemic control, is unrelated to the complications examined. It
would be like looking at the effect of antibiotics on atrial fibrilla-
tion rate.
We all know our first responsibility is to our patients, and we all
come to this meeting looking for a sound bite, something we can
take home, something that we can implement in our practice. It
just worries me that the conclusion that you present, that moderate
control is ‘‘superior’’ to tight control, is a dangerous message to let
out, because the simple fact is that it is not supported by your data.
I have 3 questions. First, you cite moderate control articles from
the medical ICU literature that don’t include patients undergoing
CABG. Why should we as cardiac surgeons ignore both random-
ized and observational cardiac-specific trials totaling more than
36,000 patients that tell us that the optimal target for patients un-
dergoing CABG is in the range of 80 to 130 mg/dL in deference to
your 134 mg/dL tight glycemic control patients?550 The Journal of Thoracic and Cardiovascular SurgDr Ailawadi. Thank you for your comments. Getting back to
the comment about our use of a clinical data repository, these
data were merged with our STS database. We did use our STS
data, not purely administrative data. We actually merged the
data sets. So we believe that this actually provides better data
and more complete data, because the STS, as you know, does
not include many of these things that we are examining.
With the comment about stroke having never been associated
with glucose strategy, there was a randomized trial of 400 patients
by Gandhi published a couple of years ago comparing tight glu-
cose control with a more liberal or a more moderate glucose con-
trol, similarly to our study. It was a randomized study, and they did
find a worse stroke rate in patients with tight control. I realize that
it is not a perfect study, but that has been shown before.
In terms of the question about medical intensive care unit, if you
actually look at the NICE-SUGAR trial, although the article does
not specify the number of patients who underwent cardiac surgery,
it did include both medical and surgical patients. If you actually
look, some of the centers included were cardiovascular ICUs.
Dr Furnary. I am going to respond really quickly. First, there
were no patients undergoing CABG in that trial, or at least cer-
tainly fewer than 100. Second, the Gandhi trial only studied intra-
operative glycemic control, and the postoperative control was the
same between groups. It was a very bad study.
My next question, and I think I know your answer to this, is in
light of the serious statistical issues I have raised—and they are se-
rious—would you consider restating your conclusion and retitling
your article? Because you actually compared moderate control
with no control, not moderate to tight.
Dr Ailawadi. The moderate control was not compared with no
control; it was a more liberal control. It was essentially what was
being done for many years until data became available.
Dr Furnary. Right, so it is moderate versus liberal.
Dr Ailawadi. It was a physician-directed protocol that many
believe was the best at the time.
Dr Furnary.Would you agree that your study does not compare
moderate versus tight control?
Dr Ailawadi. I would agree that our reference group is the lib-
eral control group, not the tight control group, because the latter
cannot be a reference group with only 134 patients.
Dr Furnary. So you compared moderate control with your ref-
erence group but not moderate control with tight control?
DrAilawadi.And we compared tight control with the reference
group as well.
Dr Furnary. Thank you. So, finally, last question. With tight
control in Portland, our 3-day blood glucose average is 115 mg/
dL and our diabetes-associated CABG mortality in the last 10
years among more than 2000 such patients is 0.9%, with an STS
observed to expected ratio of 0.25, a quarter of the national average
mortality. So why do you think that the STS-derived observed to
expected ratios contained within your data, but not explicitly pre-
sented, of 13.6 for tight control, 2.3 for moderate, and 1.45 for no
control, were all significantly greater than 1?
Dr Ailawadi. Well, there are many potential reasons. Obvi-
ously, we are in a different situation, being at a training center,
than you are at your institution. And although I cannot address
that as the sole reason, an overall CABG mortality of roughly
2% is pretty similar to what the literature shows and what theery c February 2011
Bhamidipati et al Perioperative ManagementSTS shows. I know that there has been an issue to try to get it down
to 1%, and perhaps this will help us to do that, but I do believe that
tight control may not be necessary.
I would want to emphasize that glucose control is a necessary
thing. The question is, how tight do we really need to be? And if
there are worse mortalities and higher complications with a tight
strategy, then these findings of our study will be borne out in future
randomized studies. So this is not the be-all and end-all; I agree
with that. I think that this is an interesting study. We were a bit
surprised to see the findings, and I think it should lead to better
questioning in the future.
Dr Furnary. Thanks. I am sorry to rain on your parade. I think
there is another rainmaker over there.
Dr Harold L. Lazar (Boston, Mass). I just need to disclose that
we do have research support from the Eli Lilly Company but own
no stock in the company.
When I heard that Dr Furnary was going to discuss this presen-
tation, I didn’t think that I would have too much more to question
or add, but I would like to ask a couple of questions. When we
wrote the guidelines for the STS a couple of years ago, we stated
that the optimal glucose range would be between 120 to 180 mg/
dL, and we did so not really to endorse tight versus moderate
but to make it easier for people to have at least some compliance.
Subsequently, our own group has done a study in which we looked
at moderate versus aggressive control in a prospective randomized
fashion, comparing 90 to 120 mg/dL versus 120 to 180 mg/dL.
And what we found was that the tighter control group had better
control of inflammatory factors such as free fatty acids, but in re-
ality when we looked at the clinical end points and all the major
adverse cardiac and cerebrovascular events, there was absolutely
no difference.
So my first question to you is, why do you think that tight gly-
cemic control was detrimental? We have seen that it may not add
anymore—at least in the short term, we can’t comment on the long
term—but why should it be bad? And in answering this question, I
would like to ask you to focus on these points.What was the lowest
glucose level that was reached? Did you actually have a formal
protocol that actually titrated the glucose to achieve a certain
level? And how often did you measure glucose, and what did
you do when you reached the level that was lower, let’s say, than
80 mg/dL?
Dr Ailawadi. Excellent questions. So the first question is, why
dowe think this is bad? And, again, we don’t have data on the num-
ber of hypoglycemic events, but that is certainly a concern. There
has been a fair amount of literature on the effects of neuroglycope-
nia, and, many patients in our population were still in the ICU,
some of them still intubated. Those are difficult to assess, at least
clinically, and merely can be measured with a glucose measure-
ment.The Journal of Thoracic and CaIn terms of the lowest glucose level reached, we had patients
whose serum mean glucose levels were basically were as low as
about 85 to 90 mg/dL.
Did we have a formal protocol? Before 1999, it was a physi-
cian-directed protocol. It was not a protocol enforced by the insti-
tution. From 1999, on we adopted the Portland protocol, which has
since been modified as STS guidelines have improved, and we
follow the STS guidelines quite carefully.
Dr Robert Scott Kramer (Portland, Me).We need to interpret
the evidence supporting tight glycemic control with regard to the
context where execution of the protocol at the bedside is the key
to success. Well-trained and well-supervised bedside nurses can
make a significant difference in the safety of a tight glycemic con-
trol program. Some nurses canmanage an algorithm-driven insulin
drip with the skill of a pilot keeping an airplane flying straight and
level. I suspect that the NICE-SUGAR trial may have had some
problems with the execution of the protocol at the bedside, because
its hypoglycemia rate was so high. The lesson fromNICE-SUGAR
is that hypoglycemia is dangerous. Drs Furnary and Van den
Berghe and others have taught us that a tight glycemic control pro-
tocol executed well at the bedside improves outcomes.
Dr Ailawadi. I believe that we have taken glucose control very
seriously at the University of Virginia since the Portland diabetic
project was first published. We have a number of people who are
very interested in this, endocrinologists, nursing staff, and admin-
istrators, and our university is taking a very aggressive system-
wide hospital approach. So I do believe that we feel very strongly
that this is an important thing that we have undertaken.
Finally, in response to the question about how often we mea-
sure, in the past it had been a minimum of 12 measurements during
a 24-hour period. That has now increased to a minimum of 18mea-
surements during a 24-hour period.
Dr Lazar. I am anxious to add just a follow-up to that. I think
that the lack of a proper controlled regimen and not following these
patients on an hourly basis and making adjustments may be con-
tributory to some of the effects, because that is where people
who have noted problems with tight glycemic control in surgical
patients have gotten into trouble.
I guess my second question is, as we know, tight glycemic con-
trol is not only important in the first 24 hours but is important after
the first 24 hours and before the patient goes home. So what pro-
tocols did you have in effect to look at the effect of glycemic con-
trol once the patient has left the ICU?
Dr Ailawadi. Essentially our strategy is when patients are re-
ceiving insulin infusions, we do get hourly blood glucose levels.
When patients get out of the ICU from postoperative day 1 to 3,
they are transitioned gradually to a sliding scale and the insulin
infusion is turned off. This is all by protocol.rdiovascular Surgery c Volume 141, Number 2 551
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